New research on pulmonary hypertension ahead of 'Heart Walk' - WTNH.com

New research on pulmonary hypertension ahead of 'Heart Walk' - WTNH.com

New research on pulmonary hypertension ahead of 'Heart Walk' - WTNH.com

Posted: 29 Apr 2019 08:39 AM PDT

(WTNH) - New research is underway in Connecticut for pulmonary hypertension; a devastating disease that lacks a definitive cure.

Dr. Indy Singh is part of a new team with Yale New Haven Hospital called "Cure Pulmonary Hypertension and Right Heart Failure"  which aims to raise awareness and find new treatments through research. The team is currently the top findraising team from Yale. 

The Greater New Haven Heart Walk through the American Heart Association will take place on Saturday, May 4th at Savin Rock Park in West Haven. Registration begins at 9:00am, and the walk steps off at 10:00am. Click here to sign up.

Not-operated chronic thromboembolic pulmonary hypertension | The Journal of Heart and Lung Transplantation - MD Linx

Posted: 29 Apr 2019 04:43 AM PDT

Advertisement

Researchers analyzed 343 newly diagnosed consecutive patients with not-operated chronic thromboembolic pulmonary hypertension (CTEPH) who were followed up in the French Reference Center for Pulmonary Hypertension in order to determine the prognostic variables associated with long-term outcome in this cohort of patients. Independent predictors of survival were baseline New York Heart Association functional class, right atrial pressure, 6-min walk distance (6MWD) and diagnosis period. In the recent management era, significant improvement in survival of not-operated CTEPH patients was observed. The prognosis of non-operable CTEPH patients could be improved with new treatment options, including balloon pulmonary angioplasty.

Read the full article on The Journal of Heart and Lung Transplantationexvvdyeuxt

Comments

Post a Comment

Popular posts from this blog

Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor

Image
Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Posted: 11 Jul 2019 12:00 AM PDT For patients with severe hypoxemia with pulmonary hypertension or right heart dysfunction, inhaled epoprostenol through high-flow nasal cannula increases oxygenation, according to a study published in Pharmaceutics . The researchers of this retrospective study assessed the effect of inhaled epoprostenol using a high-flow nasal cannula on oxygenation and future mechanical ventilation in patients with hypoxemia comorbid with pulmonary hypertension or right heart dysfunction in an intensive care unit setting. A chart review was completed on adult patients who were admitted into the respiratory care department of the Rush University Medical Center for severe hypoxemia between July 2015 and April 2018 and treated with inha...
Read more

Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News

Image
Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Growing Doubt, Uncertainty Over PDE5i Use in Left Heart Disease - Medscape AnMed Health gains national recognition through the Pulmonary Hypertension Association - WSPA.com Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Posted: 12 Jun 2019 05:00 AM PDT The U.S. Food and Drug Administration (FDA) has approved Novitium Pharma 's generic sildenafil for oral suspension at a dose of 10 mg/mL for the treatment of pulmonary arterial hypertension (PAH). This product, which had been designated a competitive generic therapy by the FDA, is the first approved generic equivalent to Pfizer 's Revatio , a vasodilator agent that induces blood ves...
Read more

Analysis: Large pharma companies do little new drug innovation - STAT

Image
Analysis: Large pharma companies do little new drug innovation - STAT Analysis: Large pharma companies do little new drug innovation - STAT Gene Therapy Takes Center Stage at 2019 NORD Summit - Pulmonary Hypertension News People Living With Type 2 Diabetes Want Information and Empathy From Their Doctors More Than New Medications - PRNewswire Analysis: Large pharma companies do little new drug innovation - STAT Posted: 10 Dec 2019 01:51 AM PST L arge pharmaceutical companies oppose legislation being considered by Congress to lower the prices of prescription drugs. Reducing their revenues, they contend, will reduce their investment in drug development and the discovery of new medicines, and thus lead to a decline in drug innovation. If that argument is credible, there should be evidence to show that the large pharmaceutical companies are responsible for discovering innovative new drugs. To test that claim, we examined the...
Read more